Method for mammoplasty

FIELD: medicine.

SUBSTANCE: skin is cut along the areola. Penetration is performed through the incision into the retromammary space, a cavity for the implant is formed and drained. The implant is placed into the cavity, fibrin glue is injected into the cavity. The MG is brought to the given shape, fixed and sutured, the incision is glued. At that, 12-14 days prior to the operation, the MG surface is divided into squares with side length of ~ 2.0 cm and a mesh is applied. At the center of each square, botox is injected at a rate of 2.0-2.5 units per square. Also, botox is injected in the large pectoral muscle at a rate of 20-30 units per muscle. In addition, during the operation, prior to implant insertion into the cavity, botox injection is repeated at a rate of 20-30 units per muscle in the base and along the fibers of the large pectoral muscle. Fibrin glue is used in a mixture with a solution of a nonpolarizing muscle relaxant, and the cavity is washed with an antibiotic solution before drying.

EFFECT: method has a high aesthetic effect, ensures the stability of the mammary gland with the necessary shape, excludes scars on the incision site, allows to significantly reduce postoperative rehabilitation and minimize or avoid postoperative pain sensations, local inflammatory processes and discomfort.

3 cl, 19 dwg, 3 tbl, 3 ex

 



 

Same patents:

FIELD: veterinary medicine.

SUBSTANCE: treatment is carried out with an aqueous solution of the preparation "Biopag-D" at a concentration of 4-2% by drifting animals through the baths with the solution having the immersion depth up to the carpal joint.

EFFECT: invention enables to treat efficiently and stress-free and prevent treatment of diseases of hooves and dew claws of animals.

3 cl, 5 dwg, 4 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: stimulating the excised liver regeneration is ensured by a 70% hepatectomy into a laboratory animal on the second day of the experiment. A liver regeneration stimulator is presented by L-norvaline administered intragastrically in a daily dose of 10.0 mg/kg every 46 hours for the first 7 days of the experiment.

EFFECT: method provides the effective stimulation of the excised liver regeneration evidenced by reducing the animals' lethality, improved hepatic microcirculation, reduced manifestation of cytolysis and enhanced synthetic function of the liver.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to therapeutic dentistry, and can be used for the local treatment of chronic gingivitis caused by tobacco smoking in young individuals. That is ensured by a preparatory procedure of luminal-dependent chemiluminescence of the oral fluid aiming at a maximum burst and a glow light sum. If the maximum burst falls within the range of 3.3 to 18.15 standard units, whereas the glow light sum ranges from 8.2 to 40 standard units, an antioxidant therapy is conducted by using a transverse gingival mucosa electrophoresis on 5% aqueous propolis by means of jaw electrodes in a tray at a current intensity of 0.5-1 mA and an exposure of 8-10 minutes. A polarity is alternated with a positive pole to be taken the first. The therapeutic course makes 4 procedures every second day. Colgate Propolis Toothpase and Mouthwash are used additionally during 30 days. If the maximum burst is from 0.8 to 1.24 standard units, whereas the glow light sum ranges from 3.34 to 7.5 standard units, a pro-oxidant therapy is required by using an exposure to magnetic infrared laser (MIL) light covering a projection of gums and generated by Optodan laser with a periodontal attachment The exposure parameters: 2-2,000 Hz in segments, 2 minutes per each segment, no more than 12 minutes per 1 procedure. The therapeutic course makes 4 procedures every second day. Parodontax Toothpase and Mouthwash are used additionally during 12 days.

EFFECT: method simplifies and reduces the length of the treatment in the given category of patients.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to oxazolopyramidine compounds of formula I, where A represents O; R1 is selected from phenyl or pyrimidine, which are optionally substituted with R11; R2 represents phenyl, which is optionally substituted wby 1-3 ring carbon atoms with similar or different substituents R22, R11 represents halogen; R22 is selected from hydroxy group, (C1-C4)-alkyl, which is optionallysubstituted with 1-3 atoms of fluorine, (C1-C4)-alkyloxy, (C1-C4)-alkyl-S(O)m-; m equals 2. Invention also relates to pharmaceutical composition, which contains formula I compounds, and to method of obtaining formula I compounds.

EFFECT: formula I compounds, intended for activation of EDG-1 receptor and applied for wound healing.

15 cl, 2 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to oxazolopyramidine compounds of formula (I), where A represents O; X represents (C1-C6)-alkanediyl or (C1-C6)-alkanediyloxy, where oxygen atom of (C1-C6)-alkanediyloxy is bound to group R2; Y represents pyrrolidinyl; R1 represents (C1-C4)-alkyl; R2 represents phenylene, optionally substituted by one or two carbon atoms in ring with similar or different substituent R22; R3 is selected from group, which consists of cycloalkyl-CuH2u-, where u equals 1; radical of saturated 3-10-member monocyclic ring, phenyl or pyridyl, where ring radical is optionally substituted by one or two carbon atoms of ring with substituent R31; R4 represents hydrogen; R22 represents (C1-C4)-alkyl; R31 is selected from group, which consists of halogen and (C1-C4)-alkyl. Invention also relates to (S)-l-[2-(2,6-dimethyl-4-{5-[methyl-(3,3,3-trifluoropropyl)amino]-7-propoxyoxazolo[5,4-d]pyrimidine-2-yl}phenoxy)acetyl]pyrrolidine-2-carboxylic acid, pharmaceutical composition and to method of obtaining compounds of formula (I) .

EFFECT: compounds of formula (I), intended for activation of EDG-1 receptor and applied for wound healing.

16 cl, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to veterinary and can be applied in animal-breeding for stimulation of metabolic processes, and growth activity of calves. Medication for stimulation of metabolic processes and growth activity of calves includes succinic acid as energetic stimulator, with application of citric acid as activator of succinic acid, beetroot molasses as carbon component, and methionine and sodium chloride as stimulators of digestion system.

EFFECT: application of invention makes it possible to ensure expressed acceleration of growth energy in early postnatal period.

3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: cytoflavin is administered into laboratory animals (rats) daily immediately before overheating in an air laboratory thermostat at +401-2C for 45 minutes. The preparation is administered intraperitoneally in a dose of 100 mg/kg of body weight for 14 days.

EFFECT: higher body adaptability by increasing antioxidant activity and reducing a rate of lipid peroxidation products accumulation with underlying thermal exposure.

4 tbl

FIELD: medicine.

SUBSTANCE: minor amputation of the foot with the further necrectomy is performed. After the application of an antimicrobial bandage and drainage, the wound is hermetised from the environment by the creation of a negative pressure above the wound in a combination with drug treatment. The reatment is performed in two steps. At the first step the wound with the antimicrobial bandage and drainage is first hermetised from above with an adhesive film, with the creation and support of the negative pressure not lower than 80 mm Hg. Urokinase 500000 U is additionally introduced daily intravenously by drop infusion per 100 ml of physiological solution, Vessel-Due-F in a dose of 600 LU per 100 ml of physiological solution and VAP 20 - alprostadil in a dose of 40 mcg per 100 ml of physiological solution. In addition Antistax in capsules is introduced to the patient. At the second stage active 24-hour vacuum aspiration with the change of the negative pressure from 10 to 80 mm Hg within a day is carried out. Additionally introduced is Vessel-Due-F in a dose of 1 capsule with 250 LU 2 times per day between meals and Antistax. At the first and second stages Antistax is introduced in a dose of 2 capsules in the morning 30-40 minutes before meal, daily. Duration of each stage constitutes not less than 7 days.

EFFECT: increase of the treatment efficiency due to the complete and timely purification of the wound from pathological exudates, elimination of the progression of the purulent-necrotic process, increase of the regenerative activity of tissues, activation of local immunity, recovery of microcirculation and oxygenation of the affected tissues.

2 cl, 2 ex

FIELD: medicine.

SUBSTANCE: method involves professional oral hygiene is carried out consisting in ultrasonic removal of supra- and subgingival dental deposits and polishing of supragingival teeth. Bite splinting and recovery of dentition integrity may be required. After dissecting a mucoperiosteal flap according to the known technique, an incision area is sanitated by means of a photodynamic therapy (PDT). The PDT is conducted with the use of a diode laser at wave length 6605 nm and emitting power 0.5-1.0 Wt. The photosensitiser "Photoditasin" in the form of 0.5% gel is introduced by means of a cannula into dental gaps, under the dissected segments of the flap and onto the mucosal tissue for 5 minutes. The photosensitiser is washed out, and the gingival pockets are repeatedly exposed to laser light for 2-3 min in the same environment. Sterile osteoplastic material is introduced into bone defects, and the flap is sutured together.

EFFECT: effective cleansing of the surgical area, eliminating the periodontal inflammation, stimulating tissue osteogenesis and regeneration, stabilising the processes of bone tissue absorption of alveolar interdental septa and preserving the tissues.

2 cl, 1 ex

FIELD: medicine.

SUBSTANCE: to correct pathologic changes in the condition of viable offspring under a cytostatic impact the medication glutoxim is introduced to female rats in a dose of 50 mcg/kg 5 days before and 5 days after the introduction of the cytostatic medication vepesid. The latter is introduced once intravenously in a maximal tolerable dose, equal to 30 mg/kg. It has been established that glutoxim can be applied as means for the correction of pathologic changes in the viable offspring of rats, obtained from coupling 3 months after the cytostatic impact.

EFFECT: application of glutoxim as the means of corrective therapy makes it possible to increase efficiency and reduce its side effects.

6 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to haematology. The cryogenic preservation of haematopoietic umbilical cord stem cells is carried out with a cryoprotectant solution - dimethylsulphoxide - added to a suspension of nuclear cells with the haematopoietic stem cells. That is followed by preparing for freezing by cooling the stem cell suspension in a cooling chamber to a temperature of +4C. The multi-staged freezing of the stem cell suspension involves using a cryoprotectant solution that is 55% dimethylsulphoxide with 5% dextrane 40, which is added into a suspension of a leukocyte concentrate with the stem cells packed in a cryobag. That is followed by mixing mechanically in a mixing apparatus and added with a cryogenic preserving agent at a temperature of +4C, de-aerating the cryobag with releasing a portion of the suspension, closing the bag, sealing it and placing into a shrink bag and freezing within several stages with computer assistance. At the first stage, the stem cell suspension mixed with the cryoprotectant solution (hereinafter referred to as a sample) is kept for 10 min at a temperature of +4C, frozen at 1C/min to a temperature of -12C, cooled down at 15C/min to a temperature of -60C; after the sample is unfrozen at 10C/min, it is cooled down at 1C/min to -60C; at the end of the freezing programme, the sample is cooled down at 3C to -100C. Upon completion of the freezing programme, the sample placed into a cryobox is placed into a quarantine vacuum flask containing liquid nitrogen to determine test results for the presence or absence of infectious agents and bacteriological and mycotic contamination. At the end of the quarantine period, the haematopoietic umbilical cord stem cell sample is transported into the vacuum flask containing liquid nitrogen for long storage at min -150C with negative test results.

EFFECT: invention enables increasing the cells viability.

1 tbl, 1 dwg

FIELD: medicine.

SUBSTANCE: method of obtaining encapsulated native blood, which is characterised by the fact that suspension of native blood in diethyl ether is dispersed in mixture of sodium carboxymethylcellulose in benzene, in presence E472, mixed, with pouring hexane and water to obtained mixture, obtained suspension is filtered and dried under specified conditions.

EFFECT: method makes it possible to simplify and accelerate process of obtaining encapsulated native blood.

2 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, namely to method of obtaining encapsulated native blood. Method of obtaining encapsulated native blood is characterised by the fact that suspension of native blood in diethyl ether is dispersed into mixture of sodium carboxymethylcellulose in benzene in presence of E472, mixed, with the following pouring of hexane and water to obtained mixture and further filtration and drying of obtained suspension under specified conditions.

EFFECT: method makes it possible to simplify and accelerate process of obtaining encapsulated native blood.

4 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: method of treating chronic generalised periodontitis includes the influence on an affected area by the therapeutic diode laser "HELBO" 2075 F/Theralite" with photosensitase "HELBO Blue Photosensitizer", with the application after the laser influence on the periodontium affected area of an adhesive gingival bandage, to prepare which the antioxidant "Melaxen", kalanchoe sap, glycosamine hydrochloride, dimethylsulphoxide, water dentine and solcoseryl dental adhesive paste are applied in specified quantities.

EFFECT: achievement of an anti-inflammatory, antiseptic and reparative effect, which makes it possible to stop inflammation in the tissues of periodontium and obtain stable long-lasting remission.

1 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmacology, namely represents an additive for an erythrocyte-rich fluid. The additive is prepared by adding a hemolysis inhibitor and a surfactant into a blood storage solution. The HLB value of the surfactant makes not less than 13; while the oxyethylene group number in a hydrophilic segment of the molecular structure of the surfactant is not less than 20. The hemolysis inhibitor represents an acetic acid derivative in the form of vitamin E.

EFFECT: additive provides the high-efficacy inhibition of hemolysis and the excellent erythrocyte storage characteristic.

7 cl, 6 dwg, 3 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and concerns a method for making an activated leukocyte composition involving human leukocyte incubation, exposure to hypotonic shock and addition of physiologically acceptable saline in an amount sufficient for the reconstitution of isotonicity, to the leukocytes. The group of inventions also concerns using: the activated leukocyte composition in preparing a drug for wound healing; a wound healing dressing containing the above composition.

EFFECT: group of inventions provides preparing the composition containing a 90 times increase of the leukocyte count as compared to the known state-of-the-art methods.

16 cl, 3 dwg, 6 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: mixture of 0.5% Novocaine or 0.25% Lidocaine 19.0ml and venous autoblood 1.0 ml is administered into the acupuncture points fu-tu and zu-san-li once every day or every second day in total number of blocks 8-16, in an amount of 5 ml into each point at a penetration depth of 1.5-2.0 cm.

EFFECT: reducing pain syndrome and oedema of paraarticular tissues, improving support ability of the lower extremities and knee joint functions by improving microcirculation in the lower extremities.

4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to pharmaceutical industry, namely to a preparation for treating an inflammatory condition related to ischemia. A pharmaceutical preparation for treating the internal inflammatory condition related to ischemia containing: a) normal saline containing at least 105 peripheral mononuclear cells (PMC) or their population per one ml, or b) supernatant of normal saline a), wherein normal saline a) is prepared by culturing the PMC or their population in normal saline free from PMC-proliferating or PMC-activating substances; the PMC or their population is cultured in the environment causing the pre- or intra-culture stress. Using the preparation for producing a therapeutic agent for treating the internal inflammatory condition related to ischemia. A method for preparing the pharmaceutical preparation.

EFFECT: pharmaceutical preparation possesses higher clinical effectiveness in the internal inflammatory processes related to ischemia.

13 cl, 20 dwg, 6 ex

FIELD: food industry.

SUBSTANCE: biologically active food additive contains dry blood of antler deer, an antler concentrate and honey at the following components ratio, wt %. antler concentrate - 8-10; dry blood - 2-3; honey - 87-90.

EFFECT: invention allows to produce an additive having the optimal ratio of components and having high adaptogenic and tonic properties.

4 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to field of veterinary. Claimed method includes obtaining antiplacental blood (APB) from young healthy horse 14 days after subcutaneous double introduction of placentolysate of cows, which contains parts of cotyledons and caruncles, with 14-day interval in dose 20 ml, and method of treatment and prevention of afterbirth retention, uterus subinvolution and postnatal endometritis in cows by application of antiplacental blood (APB), stimulating postnatal involution of genitals of newly calved cows, which is introduced subcutaneously in the area of neck two times in dose 10 ml, with 6 day interval.

EFFECT: application of antiplacental blood (APB) reduces duration of postnatal involution of genitals, which makes it possible to prevent and reduce terms of treatment of ill cows in case of afterbirth retention, uterus subinvolution and postnatal endometritis.

2 cl

FIELD: medicine.

SUBSTANCE: pre-operative fasting venous blood 1 ml is sampled at room temperature 20-24C into an anticoagulant-free vacuum system (test tube). The test tubes are delivered in a sealed container at temperature 2-8C for 2 hours to a laboratory for immunoenzyme assay and analysed to determine anti-thyroid stimulating hormone receptor antibodies. If the antibody level is 1.5 units/l or more, a thyroidectomy is performed, whereas the antibody level of less than 1.5 units/l requires performing a subtotal thyroid resection according to standard techniques.

EFFECT: invention enables reducing a probability of recurrent thyrotoxicosis in the patients after subtotal thyroid resection.

1 ex

Up!